Valiant Laboratories Ltd

Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross—a technical indicator where the 50-day moving average crosses below the 200-day moving average—highlighting a potential shift towards a sustained bearish trend and long-term weakness in the stock’s price trajectory.

Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 27 Jul 2026. This revision reflects deteriorating technical indicators, weak financial trends, expensive valuation metrics, and poor quality fundamentals, signalling heightened risks for investors amid challenging market conditions.

Valiant Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 July 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

At Rs 59.15, sellers were still queuing — but there were no buyers willing to take the other side. Valiant Laboratories Ltd locked at its lower circuit of 5% on 24 Jul 2026, with unfilled sell orders and a frozen price.

Valiant Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 July 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 14 July 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating by MarketsMOJO as of 2 July 2026. The revision reflects deteriorating technical indicators, expensive valuation metrics, weak long-term fundamentals, and a faltering financial trend despite recent quarterly gains. This comprehensive analysis explores the four key parameters that triggered the downgrade and what it means for investors.

Valiant Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 June 2026, providing investors with an up-to-date view of the company’s performance and outlook.

At Rs 64.60, sellers were still queuing — but there were no buyers willing to take the other side. Valiant Laboratories Ltd locked at its lower circuit of 5.0% on 15 Jun 2026, with unfilled sell orders and a frozen price, signalling persistent selling pressure in a micro-cap stock with limited liquidity.

The 50-day moving average has crossed above the 200-day for Valiant Laboratories Ltd, signalling a golden cross on 12 Jun 2026. Yet, the broader technical picture is conflicted, with weekly and monthly indicators sending mixed messages, and the stock’s micro-cap status adding a layer of caution to interpreting this signal.

Valiant Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 8 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 June 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

At Rs 69.27, Valiant Laboratories Ltd found itself locked at its lower circuit limit of 5% on 10 Jun 2026, with persistent selling pressure overwhelming demand and leaving unfilled supply on the exchange floor.

Valiant Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Valiant Laboratories Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 20 May 2026, reflecting a complex interplay of improved quarterly financials but deteriorating quality and valuation metrics, alongside mixed technical indicators. Despite a positive financial trend in the latest quarter, concerns over long-term fundamentals and expensive valuation have weighed heavily on investor sentiment.

Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its valuation metrics shift markedly, moving from an already expensive rating to very expensive territory. Despite a recent downgrade in its Mojo Grade from Strong Sell to Sell, the stock has delivered mixed returns compared to the broader Sensex, prompting investors to reassess its price attractiveness amid challenging fundamentals and peer comparisons.

Valiant Laboratories Ltd has seen its quality grade improve from below average to average, reflecting a nuanced shift in its business fundamentals. While certain key metrics such as sales and EBIT growth have strengthened considerably, concerns remain around returns and capital efficiency, prompting a cautious outlook despite the upgrade.